Biotin-PEG6-Thalidomide is primarily used in the field of targeted protein degradation research, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). The biotin tag allows for easy detection and purification of the compound, while the PEG6 linker provides flexibility and solubility, enhancing the molecule's ability to interact with target proteins. Thalidomide, a known ligand for the CRBN E3 ubiquitin ligase, is utilized to recruit the ubiquitin-proteasome system for the degradation of specific proteins of interest. This compound is valuable in studying protein function, identifying drug targets, and exploring therapeutic strategies for diseases caused by aberrant protein activity. Its application is significant in cancer research, neurodegenerative disease studies, and other areas where targeted protein degradation holds therapeutic potential.